COMMUNIQUÉS West-GlobeNewswire

AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
30/03/2026
– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX ® – – Reported positive FDA BPD Type 2a meeting, with FDA [...]
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
30/03/2026
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting [...]
Invivyd Announces Presentation at the World Vaccine Congress Washington
30/03/2026
Chief Scientific Officer, Robert Allen, Ph.D., presented as part of the “Antibodies for Infectious Disease Workshop” at the World Vaccine Congress Washington Presentation titled “Developing mAb Therapies that Keep Pace [...]
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
30/03/2026
MENLO PARK, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, [...]
Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
30/03/2026
IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first [...]
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
30/03/2026
MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of the sale of Cyprium’ [...]
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
30/03/2026
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an [...]
Children’s National Hospital announces new pain management center to help children and their families reclaim their lives from chronic pain
30/03/2026
Supported by an $8.895 million investment, new center will deliver comprehensive, multidisciplinary care for children and adolescents experiencing acute and chronic pain Washington, DC, March 30, 2026 (GLOBE NEWSWIRE [...]
IBA – ACQUISITION OF OWN SHARES
30/03/2026
Louvain-la-Neuve, Belgium, March 30 th , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
Terra Pharm Medical Marijuana Organization Opens Cultivation Facility and Dispensaries in Pennsylvania
30/03/2026
Pennsylvania’s newest medical marijuana organization partners with Duquesne University Nasuti College of Osteopathic Medicine on evidence-based research. PITTSBURGH, March 30, 2026 (GLOBE NEWSWIRE) -- Terra Pharm, [...]
IBA – ACQUISITION D’ACTIONS PROPRES
30/03/2026
Louvain-la-Neuve, Belgique, 30 mars 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") [...]
Major Shareholder Announcement
30/03/2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis [...]
Supported by significant progress in the financing of its industrial project in France, Carbios confirms its objective to build the Longlaville plant
30/03/2026
Carbios confirms its objective for the Longlaville plant construction project, within a project financing framework and a target of starting production by H1 2028. Carbios has a solid cash position, with around €60 [...]
Grâce à des avancées significatives dans le financement de son projet industriel en France, Carbios confirme son objectif de construction de l’usine de Longlaville.
30/03/2026
Carbios confirme son objectif concernant le projet de construction de l’usine de Longlaville, dans le cadre d’un financement de projet, avec pour objectif un démarrage de production à horizon S1 2028. Carbios dispose d’ [...]
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
30/03/2026
Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data In vitro analysis of the SeaStar Medical SCD indicates modulation of [...]
Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
30/03/2026
First patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren’s disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical [...]
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
30/03/2026
Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned [...]
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
30/03/2026
Program to be externally funded by a venture philanthropy agreement through clinical proof-of-concept, including the Phase 1/2 study planned to begin in the second half of 2026 NOVATO, Calif., March 30, 2026 (GLOBE [...]
AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)
30/03/2026
TAIPEI, Taiwan, March 30, 2026 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific antibodies, today [...]

Pages